As it stands Dexcom (NASDAQ: DXCM) is facing a series of issues. They are watching their insulin pump partners disappear one by one. They are also watching their stock go down every time someone mentions the Libre. Could this scenario force the company to do something they really don’t want to do but may have to do or risk see even further erosions in sensor sales.
Could the company extend Tandem (NASDAQ: TNDM) a lifeline?
Tandem is not yet officially gone it just looks that way. Facing increasing pressure from their creditors the company is in desperate need of . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.